

## Methodological Note

As a pharmaceutical company, SERVIER works in collaboration with various stakeholders including healthcare professionals, healthcare organizations and patient organizations to improve health and quality of life. Healthcare professionals and organizations provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and scientific experience. They should be fairly remunerated for the legitimate expertise and services they provide to the industry.

Fully aligned with the objectives of the EFPIA Code of practice, SERVIER see transparency reporting as an opportunity to demonstrate its commitment to implement, comply with and enforce the highest ethical standards.

The present document is intended to provide all methodological information relevant for interpretation of the information disclosed by SERVIER in Lithuania.

## ***I. Legal obligation***

Servier Lithuania, when declaring transferred values, follows Article 51<sup>1</sup> of the Pharmaceutical Law of the Republic of Lithuania and the Description of the procedure for providing information on transferred values to recipients, legal entity data, and personal data of healthcare and/or pharmaceutical specialists to the State Medicines Control Agency, as well as the procedure for publishing information on transferred values and personal data of healthcare and/or pharmaceutical specialists, approved by the order of the Minister of Health of the Republic of Lithuania on June 23, 2020, No. V-1537.

Servier Lithuania provides the State Medicines Control Agency with information about the values transferred to healthcare and/or pharmaceutical specialists, legal entities (transferred value recipients), and the State Tax Inspectorate with information about the support related to healthcare provided during the previous year. All this information is published on the State Medicines Control Agency's website: [Perleistos vertės - Valstybinė vaistų kontrolės tarnyba prie LR Sveikatos Apsaugos Ministerijos](#).

## II. Regulation by the EFPIA Code of Practice

Additionally, Servier Lithuania, aiming for transparency and in accordance with the EFPIA Code of practice, discloses the values transferred to Patient Organizations and Research and Development Activities, which are defined below as follows:

## 1. *Patient Organizations*

### 1.1. The following definition of Patient Organisations is provided by the EFPIA Code of practice:

*“not-for-profit organisations (including the umbrella organisations to which they belong), mainly composed of patients and/or caregivers, that represent and/or support the needs of patients and/or caregivers”*

## 1.2. Transfers of Value related to Patient Organizations

Transfers of Value disclosed by our Company consist in:

- Financial support
- Significant non-financial support
- Contracted services

- ⇒ When provided, paid or reimbursed to Patient Organizations or for their benefit, either directly or indirectly. Transfers of Value provided to Patient Organizations are disclosed on nominative basis, even when related to Research and Development activities.

## 2. Transfers of Value related to ***Research and Development Activities***

According to the EFPIA Code of practice, Research and Development activities correspond to:

- Non-Clinical Studies (laboratory),
- Clinical Trials
- Non-interventional studies that are prospective in nature and that involve the collection of patient data from or on behalf of individual, or groups of, healthcare and/or pharmaceutical specialists specifically for the study.

All non-interventional studies that do not fall within the scope of “prospective studies”, publication is made on a nominative basis. As such, retrospective studies will be disclosed under the “consultancy / fee for services” category of the disclosure template. In case it is not possible to distinguish between prospective and retrospective non-interventional studies, the disclosure of all NIS will be on an individual basis.

### **III. Disclosure's scope**

#### **1. Products concerned**

All Transfers of Value related to activities in connection with our Company's pharmaceutical products portfolio, whatever their status (Over-The-Counter pharmaceuticals or not) are included in the disclosure.

#### **2. Company concerned**

The information disclosed by our Company in the present country is provided on behalf of the Servier Group.

Servier is a Group of companies with affiliates in other countries that can initiate interactions with healthcare and/or pharmaceutical specialists, Healthcare Organisations, Professional Congress Organizers or Patient Organizations.

A Group process is implemented to ensure that the local disclosure includes all transfers of value provided by companies of the Servier Group, either established locally or in foreign countries, during the previous calendar year (from 1<sup>st</sup> January to 31<sup>st</sup> December).

#### **3. Excluded Transfers of Value**

The Transfers of Value corresponding to the following categories or provided in relation with the following activities, are not included in the disclosed information:

- Meals and drinks,
- Or any Transfer of Value which is out of the reporting scope, as defined by the EFPIA Code of practice or by law.

#### **4. ToV's Date**

As a standard rule, the date considered to prepare the disclosure corresponds to the date of the financial payment made to or for the benefit of the recipient.

Exception: when a Transfer of Value is provided in relation with the participation to an event, the date retained for the disclosure purpose will correspond to the date of the event.

#### **5. Direct and Indirect Transfers of Value**

The disclosure includes both direct and indirect Transfers of Value provided to recipients or for their benefit. In this context:

- Direct Transfers of Value are provided to the recipient by our Company directly,

- Indirect Transfers of Value are provided to the recipient through a third party. In this situation, our partners are required by contract to share with our Company all information relative to Transfers of Value in order to allow an appropriate preparation of the disclosure.

## **6. Non-monetary Transfers of Value**

- For significant non-financial support that cannot be assigned a meaningful monetary value, the description describes the non-monetary benefit that the Patient Organization receives.

## **7. Research & Development**

All kind of Transfers of Value –provided to healthcare/pharmaceutical specialists, or Healthcare Organizations in relation with Research and Development activities are disclosed in aggregate. For Transfers of Value provided to Patient Organizations in relation with Research and Development activities.

## **8. Specific Considerations:**

- **Country Unique Identifier Code (UCI)**

The allocation of a Unique Country Identifier Code is intended to facilitate the identification of recipients at country level and to prevent confusion when several recipients have the same name.

This code is optional according to the EFPIA Code of practice.  
In the present country, the UCI corresponds to: LT.

## **9. Data protection legal basis**

- **Legal obligation**

Data is processed based on the Pharmaceutical Law of the Republic of Lithuania: personal data is stored for three years from the date of its first publication on the State Medicines Control Agency's website and is destroyed in such a way that it cannot be restored. Documents containing personal data are destroyed in accordance with the procedure established by the Law on Documents and Archives of the Republic of Lithuania.

## **10. Form of Disclosure**

### **Date of Publication**

The date of publication: The State Medicines Control Agency publishes reports on transferred values to individuals on its website by August 1 of the following year, and reports on transferred values to legal entities by November 1 of the following year. It also publishes the data provided by the State Tax Inspectorate on transferred values as support according to the Law on Charity and Sponsorship of the Republic of Lithuania.

Transferred values for patient organizations and R&D are published by June 30 of the following year, following the recommendations of the local association.

## **11. Reporting Year**

The publication relates to the previous calendar year (from 1<sup>st</sup> January to 31<sup>st</sup> December).

This information will remain available on Internet for a period of 3 years after the date of the publication.

## **12. Disclosure Platform**

The publication is provided through:

- Servier's publication page on <https://servier.lt/atskleidimas/>
- The local association's website <https://vaistukodeksas.lt/atskleidimo-kodekso-atauskaitos-2023>
- the State Medicines Control Agency's website: <Perleistos vertės - Valstybinė vaistų kontrolės tarnyba prie LR Sveikatos Apsaugos Ministerijos>

## **13. Disclosure Language**

The publication is provided in Lithuanian and English.

## **14. Disclosure Financial Data**

### **Publication Currency**

The currency used for the current publication is: EUR

### **VAT**

Transferred values are disclosed including VAT if VAT is part of the transferred value.

### **Calculation Rule**

For Transfers of Value involving the use of foreign currencies, amounts are converted from the initial currency to the publication currency according to the Group Monthly Average Exchange Rate applicable at the date of the Transfers of Value.

2025-04-14